🔗 Share this article

While America proceeds with historic changes to its vaccine schedules, one figure has surfaced unexpectedly: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the global health crisis and has concentrated on possible fatalities after Covid immunization in her brief tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Schedule

Health officials had intended to announce radical revisions to the childhood vaccine schedule recently, bringing the US with the Danish national calendar, it is understood – a significant shift that would put the US at odds with many the global community with no evidence for benefit. The announcement has been pushed back until the new year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood shot schedules in the US in order to be more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent track record in pharmaceutical research, regulation or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a scientific study. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that prior appointees who led CBER have had.”

The drug center has an enormous workload at the agency, she pointed out.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and every single one must be supervised,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major management component to the job, which manages over 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” she said.

Agency Reaction and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “inquiries are based on inaccurate premises”.

“Her experience matches the responsibilities of her position,” the spokesperson stated, pointing to the months Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the agency head's recently launched priority voucher program, a contentious rapid medication authorization process that reportedly concerned her former heads. “How are these medications being picked for this voucher program? Who is making the decisions?” Dr. Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards laxer rules of most medications, aside from immunizations.”

Established Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if problematic, past, some experts have noted. She published a analysis using non-validated crowd-sourced reports to determine the frequency of myocarditis following Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new administration included altering rules for recently developed shots and halting “non-essential” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to accommodate the evidence in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined other skeptics, {like|